Obesity, reached epidemic proportions globally is often associated with life threatening comorbidities. The unavailability of safe and effective long term medications for obesity in modern pharmacotherapy forces the scientific community to explore the potential of Ayurvedic traditional healers as they are considered safe and effective. To explore the anti-obesity potential of aqueous extract of aerial parts of Achyranthes aspera L. (AEAA), a traditional healer in high fat diet (HFD) induced obese rats. AEAA was prepared and subjected to in-vitro pancreatic lipase inhibition assay and in-vivo anti-obesity studies. For in-vivo studies, HFD fed obese prone Wistar albino rats were divided into five experimental groups (Group II to VI): animals fed with standard pellet chow served as normal control (Group I) while, animals continued with HFD alone served as obese control (Group II); Group III, IV and V were administered AEAA at a dose of 100, 200 and 300 mg/kg b.w. respectively along with HFD; and animals administered orlistat (30 mg/kg bw) along with HFD served as standard control (Group VI). All the drugs were administered orally once a day for a period of 60 days. At the end of the experimental period various physical, biochemical and histopathological observations were made. In-vitro studies showed AEAA partially but not significantly inhibited the activity of pancreatic lipase. Data of in-vivo studies revealed, significant reduction in body weights, fat pad weights and organ weights upon AEAA treatment. Elevated levels of glucose, insulin, leptin, lipid profiles and antioxidant status were also brought back to normal. The obtained results clearly suggested that AEAA possess pronounced anti-obesity potential.

中文翻译：

---

牛膝草水提物的抗肥胖潜力评估。在高脂饮食诱导的肥胖大鼠中

肥胖症在全球范围内达到流行病的程度，通常与威胁生命的合并症相关。在现代药物疗法中，由于缺乏安全有效的肥胖长期药物，迫使科学界探索阿育吠陀传统治疗师的潜力，因为它们被认为是安全有效的。为了探讨高脂饮食（HFD）诱导的肥胖大鼠中传统的治疗者牛膝草（Achyranthes aspera L.）（AEAA）空中部分水提物的抗肥胖潜力。制备AEEA并进行体外胰腺脂肪酶抑制测定和体内抗肥胖症研究。为了进行体内研究，将以HFD喂养的肥胖俯卧Wistar白化病大鼠分为五个实验组（II至VI组）：以标准颗粒食物喂养的动物作为正常对照组（I组），继续用HFD作为肥胖对照的动物（第二组）；III，IV和V组分别以100、200和300 mg / kg bw的剂量与HFD一起给予AEAA；给予奥利司他（30 mg / kg体重）和HFD的动物作为标准对照组（VI组）。所有药物每天口服一次，共60天。在实验期结束时，进行了各种物理，生化和组织病理学观察。体外研究显示，EAEA可以部分但不显着抑制胰腺脂肪酶的活性。体内研究的数据显示，经AEAA治疗后，体重，脂肪垫重量和器官重量显着降低。葡萄糖，胰岛素，瘦素，脂质分布和抗氧化剂状态的升高也恢复了正常。